Urge your Representative and Senators to Support Improved Medicaid Coverage of Clinical Trials!

The CLINICAL TREATMENT Act, H.R. 913, was introduced by Representatives Ben Ray Lujan (D-NM-03) and Gus Bilirakis (R-FL-12) to guarantee coverage of the routine care costs of clinical trial participation for Medicaid enrollees with a life-threatening condition or disability.

Clinical trials are a critical weapon in the fight against ME/CFS.
Medicaid insures nearly one-fifth of the U.S. population and is the only major payer that is not required by federal law to provide coverage of the routine care costs for participating in a clinical trial. Improved access and coverage of clinical trial participation benefits ME/CFS patients and helps reduce the cost of clinical trials. This is vital for under-funded diseases, like ME/CFS, which struggles to secure funds for clinical trial research.
Medicaid serves a large portion of under-represented minorities, ethnicites, and disabilities that are not well represented in traditional clinical trial enrollment. The Clinical Treatment Act (H.R. 913) is one step towards improving the representation of ME/CFS patients in clinical trials and reducing the cost of ME/CFS clinical trials in the future.

Your Informationclick here for blank form
All fields are required to ensure we can deliver your message directly to your elected officials.

Your Message

Your Elected Officials